# Mipletamig

Source: https://onco.cc/drugs/mipletamig/  
OnCo record `mipletamig` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mipletamig is a two-armed protein from Aptevo Therapeutics that holds a leukaemia cell and a T cell together so the T cell kills it. It is in an early trial with standard drugs in newly diagnosed acute myeloid leukaemia.

## Summary

Mipletamig is a CD123 x CD3 T cell engager from Aptevo Therapeutics. After phase 1 dose escalation and expansion, Aptevo is running RAINIER, a phase 1b/2 dose-optimisation trial started in August 2024 in frontline acute myeloid leukaemia, combining mipletamig with venetoclax and azacitidine in patients unfit for intensive chemotherapy, to set a recommended phase 2 dose. The company reports favourable initial results; they are its own.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: APVO436
- Tags: pipeline
- Modality: Bispecific T cell engager
- Mechanism: A CD123 x CD3 bispecific protein built on Aptevo's ADAPTIR platform, with a CRIS-7 CD3-binding domain, that redirects T cells to kill CD123-expressing leukaemia cells.

## Notes

- The code APVO436 is the name under which the molecule was earlier reported; the August 2026 filing uses mipletamig.

## Sources

- SEC: Aptevo Therapeutics Form S-1, August 2026: https://www.sec.gov/Archives/edgar/data/1671584/000119312526361103/apvo-20260821.htm

## Connected records

- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD123](https://onco.cc/targets/cd123/), [CD3](https://onco.cc/targets/cd3/)
- companies: [Aptevo Therapeutics](https://onco.cc/companies/aptevo-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/mipletamig.json